Assessment of the association between the Implant Disease Risk Assessment (IDRA) tool and peri-implantitis: a retrospective cohort study with up to 8 years of follow-up.

The aim of this study was to evaluate the accuracy of the Implant Disease Risk Assessment (IDRA) tool in predicting the occurrence of peri-implantitis in patients who have received at least one implant, with a follow-up of up to 8 years. The records of patients who received one or more implants in the periodontology or oral surgery department of Saint Joseph University of Beirut between 2014 and 2018 were collected. Parameters related to the IDRA tool were obtained and the risk level calculated. Patients were recalled to assess their peri-implant status. The association between the IDRA risk level and the incidence of peri-implantitis was estimated. Overall, 145 patients were included in the study. A statistically significant association was found between the IDRA risk levels and the incidence of peri-implantitis (P = 0.003). High risk patients had 5.2 times higher odds of developing peri-implantitis than low-to-moderate risk patients (P < 0.001). Receiver operating characteristic curve analysis demonstrated a 69% probability that IDRA can identify patients at risk of developing peri-implantitis (P = 0.003). Further analysis found the percentage bleeding on probing to be the only significant IDRA vector. Within the limitations of this study, the IDRA tool is considered potentially useful for identifying patients at risk of developing peri-implantitis. It may serve as one component of a comprehensive peri-implant assessment, pending further enhancement of its predictive precision. Moreover, this tool can be considered before implant placement and during the periodontal maintenance phase. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04888572.

Characterization of the transient middle cerebral artery occlusion model of ischemic stroke in a HuR transgenic mouse line.

This set of experiments characterizes a model of transient cerebral ischemic stroke in a transgenic (Tg) mouse line in which the glial fibrillary acidic protein (GFAP) promoter is utilized to drive expression of a human RNA-binding protein, HuR. Additionally, the effect of cerebral ischemia on the expression of endogenous Hu proteins is presented.

Unusual presentation of a sarcoid patient: multiple arterial and venous thrombosis with chest lymphadenopathy.

We depict a case of a 32 year old Mediterranean man, presenting with pulmonary embolism, and diffuse arterial thrombosis of the lower extremities. CT angiography revealed bilateral pulmonary artery occlusions and a mediastinal lymphadenopathy. Duplex Ultrasound of the lower extremities showed no deep venous thrombosis, but occluded popliteal arteries bilaterally with extension to the right distal superficial femoral artery. Mediastinoscopy with hilar lymph node biopsy showed noncaseating granulomas consistent with sarcoidosis. Thrombophilia profile revealed factor II, MTHFR, and factor XIII gene mutations with markedly elevated homocysteine level of 139 mumol/l. This is an atypical rare case of sarcoidosis presenting with pulmonary embolism and multiple arterial thrombosis.